RATIONALE: Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening. OBJECTIVES: To assess SAA as a biomarker of AECOPD. METHODS: Biomarkers were assessed (1) cross-sectionally (stable vs. AECOPD; 62 individuals) and (2) longitudinally with repeated measures (baseline vs. AECOPD vs. convalescence; 78 episodes in 37 individuals). Event severity was graded (I, ambulatory; II, hospitalized; III, respiratory failure) based on consensus guidelines. MEASUREMENTS AND MAIN RESULTS: Presumptively newly acquired pathogens were associated with onset of symptomatic AECOPD. In the cross-sectional study, both SAA and C-reactive protein (CRP) were elevated at AECOPD onset compared with stable disease (SAA median, 7.7 vs. 57.6 mg/L; P < 0.01; CRP median, 4.6 vs. 12.5 mg/L; P < 0.01). Receiver operator characteristics analysis was used to generate area-under-curve values for event severity. SAA discriminated level II/III events (SAA, 0.88; 95% confidence interval, 0.80-0.94 vs. CRP, 0.80; 95% confidence interval, 0.70-0.87; P = 0.05). Combining SAA or CRP with major symptoms (Anthonisen criteria, dyspnea) did not further improve the prediction model for severe episodes. IL-6 and procalcitonin were not informative. CONCLUSIONS: SAA is a novel blood biomarker of AECOPD that is more sensitive than CRP alone or in combination with dyspnea. SAA may offer new insights into the pathogenesis of AECOPD.
RATIONALE: Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening. OBJECTIVES: To assess SAA as a biomarker of AECOPD. METHODS: Biomarkers were assessed (1) cross-sectionally (stable vs. AECOPD; 62 individuals) and (2) longitudinally with repeated measures (baseline vs. AECOPD vs. convalescence; 78 episodes in 37 individuals). Event severity was graded (I, ambulatory; II, hospitalized; III, respiratory failure) based on consensus guidelines. MEASUREMENTS AND MAIN RESULTS: Presumptively newly acquired pathogens were associated with onset of symptomatic AECOPD. In the cross-sectional study, both SAA and C-reactive protein (CRP) were elevated at AECOPD onset compared with stable disease (SAA median, 7.7 vs. 57.6 mg/L; P < 0.01; CRP median, 4.6 vs. 12.5 mg/L; P < 0.01). Receiver operator characteristics analysis was used to generate area-under-curve values for event severity. SAA discriminated level II/III events (SAA, 0.88; 95% confidence interval, 0.80-0.94 vs. CRP, 0.80; 95% confidence interval, 0.70-0.87; P = 0.05). Combining SAA or CRP with major symptoms (Anthonisen criteria, dyspnea) did not further improve the prediction model for severe episodes. IL-6 and procalcitonin were not informative. CONCLUSIONS:SAA is a novel blood biomarker of AECOPD that is more sensitive than CRP alone or in combination with dyspnea. SAA may offer new insights into the pathogenesis of AECOPD.
Authors: Evelyn Tsantikos; Maverick Lau; Cassandra Mn Castelino; Mhairi J Maxwell; Samantha L Passey; Michelle J Hansen; Narelle E McGregor; Natalie A Sims; Daniel P Steinfort; Louis B Irving; Gary P Anderson; Margaret L Hibbs Journal: J Clin Invest Date: 2018-04-30 Impact factor: 14.808
Authors: Michelle A Erickson; Joseph Jude; Hengjiang Zhao; Elizabeth M Rhea; Therese S Salameh; William Jester; Shelley Pu; Jenna Harrowitz; Ngan Nguyen; William A Banks; Reynold A Panettieri; Kelly L Jordan-Sciutto Journal: FASEB J Date: 2017-05-22 Impact factor: 5.191
Authors: Desiree Anthony; Jonathan L McQualter; Maria Bishara; Ee X Lim; Selcuk Yatmaz; Huei Jiunn Seow; Michelle Hansen; Michelle Thompson; John A Hamilton; Louis B Irving; Bruce D Levy; Ross Vlahos; Gary P Anderson; Steven Bozinovski Journal: FASEB J Date: 2014-05-20 Impact factor: 5.191
Authors: Steven Bozinovski; Mohib Uddin; Ross Vlahos; Michelle Thompson; Jonathan L McQualter; Anne-Sophie Merritt; Peter A B Wark; Anastasia Hutchinson; Louis B Irving; Bruce D Levy; Gary P Anderson Journal: Proc Natl Acad Sci U S A Date: 2012-01-03 Impact factor: 11.205
Authors: Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy Journal: Physiol Rev Date: 2018-07-01 Impact factor: 37.312
Authors: Maria B Sukkar; Md Ashik Ullah; Wan Jun Gan; Peter A B Wark; Kian Fan Chung; J Margaret Hughes; Carol L Armour; Simon Phipps Journal: Br J Pharmacol Date: 2012-11 Impact factor: 8.739
Authors: Richard Hewitt; Hugo Farne; Andrew Ritchie; Emma Luke; Sebastian L Johnston; Patrick Mallia Journal: Ther Adv Respir Dis Date: 2015-11-26 Impact factor: 4.031